Alvotech Share Price & Technical Analysis
ALVO · $3.34 (-1.18%)
Healthcare / Drug Manufacturers - Specialty & Generic
$3.34
-1.18%
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, …
Price chart
Seasonality
May has 1 positive and 2 negative years (last 5 years shown)
0% return in May, 9% avg return in past 3 year May month.
-37% return in 2026, -4% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 6% | -25% | -13% | -6% | 0% | – | – | – | – | – | – | – | -37% |
| 25 | -5% | -9% | -15% | -19% | 44% | -20% | 1% | -9% | 1% | -5% | -12% | 0% | -47% |
| 24 | 37% | -2% | -20% | 19% | -4% | -12% | -5% | -2% | 3% | 8% | -10% | 14% | 26% |
| 23 | 19% | 16% | -8% | -23% | -14% | -9% | 10% | 2% | -8% | -3% | 12% | 16% | 8% |
| 22 | – | – | – | – | – | -14% | -1% | 13% | -24% | -9% | 5% | 54% | 24% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.07B
P/E ratio
34.15
52W high
$11.85
52W low
$3.03
Volume
1,96,894
Beta
0.21
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Alvotech share price today?
- Alvotech (ALVO) last traded around $3.34 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ALVO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ALVO. Download the app for real-time alerts.
- How can I analyze Alvotech stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.